CALIWAY BIOPHARMACEUTICALS CO L
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for … Read more
CALIWAY BIOPHARMACEUTICALS CO L (6919) - Net Assets
Latest net assets as of September 2025: NT$9.38 Billion TWD
Based on the latest financial reports, CALIWAY BIOPHARMACEUTICALS CO L (6919) has net assets worth NT$9.38 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$9.46 Billion) and total liabilities (NT$78.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$9.38 Billion |
| % of Total Assets | 99.17% |
| Annual Growth Rate | 146.8% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 57.58 |
CALIWAY BIOPHARMACEUTICALS CO L - Net Assets Trend (2021–2024)
This chart illustrates how CALIWAY BIOPHARMACEUTICALS CO L's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CALIWAY BIOPHARMACEUTICALS CO L (2021–2024)
The table below shows the annual net assets of CALIWAY BIOPHARMACEUTICALS CO L from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$9.70 Billion | +159.21% |
| 2023-12-31 | NT$3.74 Billion | +221.32% |
| 2022-12-31 | NT$1.16 Billion | +80.60% |
| 2021-12-31 | NT$644.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CALIWAY BIOPHARMACEUTICALS CO L's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5127000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$9.75 Billion | 100.58% |
| Total Equity | NT$9.70 Billion | 100.00% |
CALIWAY BIOPHARMACEUTICALS CO L Competitors by Market Cap
The table below lists competitors of CALIWAY BIOPHARMACEUTICALS CO L ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aneka Tambang (Persero) TBK (PT)
AU:ATM
|
$4.21 Billion |
|
Isupetasys
KO:007660
|
$4.21 Billion |
|
Life Time Group Holdings Inc
NYSE:LTH
|
$4.21 Billion |
|
A2 Milk Company Ltd
F:14L
|
$4.22 Billion |
|
Technip Energies N.V
PINK:THNPF
|
$4.21 Billion |
|
Thyssenkrupp AG O.N.
PINK:TYEKF
|
$4.21 Billion |
|
Bharat Heavy Electricals Limited
NSE:BHEL
|
$4.21 Billion |
|
Yuhan Corp.
KO:000100
|
$4.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CALIWAY BIOPHARMACEUTICALS CO L's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,740,950,000 to 9,696,812,000, a change of 5,955,862,000 (159.2%).
- Net loss of 588,830,000 reduced equity.
- New share issuances of 6,479,749,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-588.83 Million | -6.07% |
| Share Issuances | NT$6.48 Billion | +66.82% |
| Other Changes | NT$64.94 Million | +0.67% |
| Total Change | NT$- | 159.21% |
Book Value vs Market Value Analysis
This analysis compares CALIWAY BIOPHARMACEUTICALS CO L's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 19.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 116.23x to 19.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$1.05 | NT$121.50 | x |
| 2022-12-31 | NT$1.89 | NT$121.50 | x |
| 2023-12-31 | NT$5.37 | NT$121.50 | x |
| 2024-12-31 | NT$6.30 | NT$121.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CALIWAY BIOPHARMACEUTICALS CO L utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1325.18%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.01x
- Recent ROE (-6.07%) is above the historical average (-19.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -34.79% | -1817.76% | 0.02x | 1.11x | NT$-288.76 Million |
| 2022 | -24.58% | -2232.10% | 0.01x | 1.06x | NT$-402.58 Million |
| 2023 | -13.06% | -1254.64% | 0.01x | 1.02x | NT$-862.55 Million |
| 2024 | -6.07% | -1325.18% | 0.00x | 1.01x | NT$-1.56 Billion |
Industry Comparison
This section compares CALIWAY BIOPHARMACEUTICALS CO L's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CALIWAY BIOPHARMACEUTICALS CO L (6919) | NT$9.38 Billion | -34.79% | 0.01x | $4.21 Billion |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |